Regencell Bioscience (NASDAQ:RGC) Shares Up 7.6% – Time to Buy?

Regencell Bioscience Holdings Limited (NASDAQ:RGC)’s share price rose 7.6% during mid-day trading on Monday. The company traded as high as $10.20 and last traded at $10.32. 165,426 shares traded hands during trading, a decline of 44% from the average session volume of 294,478 shares. The stock had previously closed at $9.59.

Analysts Set New Price Targets

RGC has been the subject of several recent analyst reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Regencell Bioscience in a research report on Monday, September 21st. Wall Street Zen lowered shares of Regencell Bioscience from a “hold” rating to a “sell” rating in a research note on Saturday, July 18th. One research analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, Regencell Bioscience presently has a consensus rating of “Sell”.

Regencell Bioscience Stock Up 9.8%

The firm’s 50 day simple moving average is $6.25 and its two-hundred day simple moving average is $14.10.

Regencell Bioscience (NASDAQ:RGC) last released its quarterly earnings data on Wednesday, October 7th. The company reported ($0.01) earnings per share (EPS) for the quarter.

Institutional Inflows and Outflows

An institutional investor recently raised its stake in Regencell Bioscience stock. Bank of America Corp DE boosted its position in Regencell Bioscience Holdings Limited (NASDAQ:RGC) by 59,113.8% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 17,172 shares of the company’s stock after acquiring an additional 17,143 shares during the period. Bank of America Corp DE’s holdings in Regencell Bioscience were worth $437,000 as of its most recent SEC filing. 0.13% of the stock is owned by institutional investors.

About Regencell Bioscience

Regencell Bioscience Holdings Limited is a clinical-stage biotechnology company focused on developing traditional Chinese medicine (TCM) treatments for neurocognitive disorders and degenerative conditions. Its research has centered primarily on conditions such as dementia and attention-deficit/hyperactivity disorder (ADHD), with the goal of developing herbal formulations that may address underlying symptoms and disease-related challenges.

The company’s product development programs include proprietary TCM formulations intended for neurological and cognitive conditions.